Canada markets closed
  • S&P/TSX

    21,212.39
    +24.20 (+0.11%)
     
  • S&P 500

    4,549.78
    +13.59 (+0.30%)
     
  • DOW

    35,603.08
    -6.26 (-0.02%)
     
  • CAD/USD

    0.8083
    -0.0038 (-0.46%)
     
  • CRUDE OIL

    82.65
    -0.77 (-0.92%)
     
  • BTC-CAD

    77,473.17
    -4,453.39 (-5.44%)
     
  • CMC Crypto 200

    1,484.94
    -49.71 (-3.24%)
     
  • GOLD FUTURES

    1,784.10
    -0.80 (-0.04%)
     
  • RUSSELL 2000

    2,296.18
    +6.42 (+0.28%)
     
  • 10-Yr Bond

    1.6760
    +0.0400 (+2.44%)
     
  • NASDAQ

    15,215.70
    +94.02 (+0.62%)
     
  • VOLATILITY

    15.01
    -0.48 (-3.10%)
     
  • FTSE

    7,190.30
    -32.80 (-0.45%)
     
  • NIKKEI 225

    28,708.58
    -546.97 (-1.87%)
     
  • CAD/EUR

    0.6952
    -0.0013 (-0.19%)
     

COVID shot drives CanSinoBIO's first six-month profit since at least 2019

·1 min read
FILE PHOTO: China's vaccine specialist CanSino Biologics Inc in Tianjin

BEIJING (Reuters) - Chinese vaccine maker CanSino Biologics Inc (CanSinoBIO) said on Friday it had returned to operating profit of 802.3 million yuan ($123.79 million) in the first six months of 2021, driven by use of its COVID-19 shot. That compared with 123.0 million yuan of operating loss in the same period a year ago, CanSinoBIO said in a filing in the Hong Kong stock exchange. It marks the first six-month profit since at least 2019. The firm is yet to achieve full-year profits since it went public in 2018 in Hong Kong.

It reported 937.1 million yuan profit and total comprehensive income for the first six months of 2021. Its single-dose COVID-19 shot, named Ad5-nCoV, has been approved for use in countries including China, Mexico, Pakistan and Chile. The vaccine approvals were one of the major drivers for the sixth-month profit, CanSinoBIO said.

($1 = 6.4813 Chinese yuan renminbi)

(Reporting by Roxanne Liu and Ryan Woo; Editing by Catherine Evans)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting